Program Number | 2019 P 4010-2
--- | ---
Program | Supply Limits - Greater than 34 day supply for opioids at retail
Medication | Includes all salt forms, single and combination ingredient products short-acting and long-acting opioid formulations, and all brand and generic formulations
P&T Approval Date | 9/2018, 9/2019
Effective Date | 12/1/2019; Oxford only: 12/1/2019

1. **Background:**

   The Center for Disease Control (CDC) recommends that clinicians should prescribe the lowest effective dosage when opioids are started. Clinicians should use caution when prescribing opioids at any dosage and guidelines note that opioids are not first-line or routine therapy for chronic pain.

   This program allows members with a greater than 34 day supply plan at retail to receive more than a one month supply of opioids up to plan allowance.

2. **Coverage Criteria:**

   A. Greater than 34 day supply at retail will be approved based on **BOTH** of the following:

   1. The member requires a greater than one month supply of opioid medications
   2. Document the diagnosis associated with the need for pain management

   **Authorization will be issued for plans that allow a greater than 34 day supply at retail up to the plan allowance of days’ supply for 12 months.**
3. Additional Clinical Programs:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.
- Opioid Cumulative Dose Review may be in place.
- Prior Authorization/Medical Necessity may be in place.
- Prior Authorization/New to Therapy may be in place.

4. References:


<table>
<thead>
<tr>
<th>Program</th>
<th>Greater than 35 day supply for opioids at retail</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Change Control</td>
</tr>
<tr>
<td>9/2018</td>
<td>New program</td>
</tr>
<tr>
<td>9/2019</td>
<td>Annual review. No changes.</td>
</tr>
</tbody>
</table>